RT Journal Article
SR Electronic
T1 Neutrophil-to-lymphocyte, platlet-to-lymphocyte ratio and adiposityin early COVID -19
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3883
DO 10.1183/13993003.congress-2021.PA3883
VO 58
IS suppl 65
A1 Cherneva, Radostina
A1 Cherneva, Zheyna
YR 2021
UL https://publications.ersnet.org//content/58/suppl_65/PA3883.abstract
AB Background: Viral-induced hyper-inflammatory immune response plays a central role in COVID-19 pathogenesis. It is responsible for disease progression and multi-organ failure. Both obesity and immunity have been implicated in COVID-19 clinical outcome.Aim: To evaluate the prognostic value of obesity and inflammatory biomarkers in COVID-19.Material and methods: 250 patients with PCR confirmed COVID-19 were included. Participants were divided into non-severe (mild and moderate) and severe group based on clinical signs, Ro findings, arterial-blood gas analysis, oxygen supply demands on the seventh day of symptom onset. Body-mass index was used for classification. Inflammatory biomarkers were taken on admission - before treatment. C-reactive protein (CRP) and ferritin were measured. Blood count was performed, neutrophil-to-lymphocyte ratio (NLR) and platlet-to-lymphocyte ratio (PLR) were calculated.Results: 80 (32%) of the patients had normal weight; 131 (52,4%) -overweight, 39 (15,6%) - obese. Patients with non-severe disease were 142/56.8% ; severe - 108/43.2%. CRP, ferritin, NLR and PLR were higher in patients that progressed to severe COVID-19. Obesity (p-0,021) and NLR (p-0,001) correlated to disease severity. ROC showed NLR>4.02 classifies patients regarding their risk of disease progression with se=66.36%, sp=62.41%. Multivariate regression analysis showed that NLR >4.02 predicted worse clinical outcome with OR = 3.27 (95% CI 1,93 - 5,54) independently from age, body weight or treatment, which make them potential prognostic markers for worse outcome.Conclusion: NLR >4.02 may serve as an independent predictor for disease progression. in COVID-19 treatment naïve patients.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3883.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).